» Articles » PMID: 39376328

Pre and Post Covid - 19 Experience of the 'Amphotericin Sandwich' Therapy in the Management of Mucormycosis

Overview
Publisher Springer
Date 2024 Oct 8
PMID 39376328
Authors
Affiliations
Soon will be listed here.
Abstract

Mucormycosis is caused by saprophytic fungi belonging to the species mucorales. The disease commonly affects patients with immunocompromised states such as uncontrolled diabetes, blood disorders and organ transplantation recepients. The usual mode of management is by using antifungals such as amphotericin B and surgery in the form of debridement of the necrotic tissue. A study was conducted on patients of mucormycosis during the pre-Covid-19 and Covid-19 era to evaluate the effectiveness of the Sandwich Therapy of amphotericin B. The mortality rate was found to be 3.57% during the pre- Covid-19 period and 18.8% during the Covid-19 period. This is very low as opposed to 50% quoted by many other studies. The Sandwich Therapy as discussed above for extensive mucormycosis can be useful in curtailing the disease already established to its present location and preventing its further spread either naturally or by the act of debridement per se. It also provides a sustained anti fungal umbrella in the blood to deal with the disease at microscopic level in the blood stream thus reducing mortality.

References
1.
Spellberg B, Ibrahim A . Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep. 2011; 12(6):423-9. PMC: 2947016. DOI: 10.1007/s11908-010-0129-9. View

2.
Skiada A, Pagano L, Groll A, Zimmerli S, DuPont B, Lagrou K . Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011; 17(12):1859-67. DOI: 10.1111/j.1469-0691.2010.03456.x. View

3.
Kontoyiannis D, Lewis R . How I treat mucormycosis. Blood. 2011; 118(5):1216-24. PMC: 3292433. DOI: 10.1182/blood-2011-03-316430. View

4.
Ruping M, Heinz W, Kindo A, Rickerts V, Lass-Florl C, Beisel C . Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother. 2009; 65(2):296-302. DOI: 10.1093/jac/dkp430. View

5.
Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll A, Skiada A . ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2016; 102(3):433-444. PMC: 5394968. DOI: 10.3324/haematol.2016.152900. View